Hyperuricaemia and gout: state of the art and future perspectives

Major progress has been made in the past decade in understanding the pathogenesis and treatment of gout. These advances include identification of the genetic and environmental risk factors for gout, recognition that gout is an important risk factor for cardiovascular disease, elucidation of the pathways regulating the acute gout attack and the development of novel therapeutic agents to treat both the acute and chronic phases of the disease. This review summarises these advances and highlights the research agenda for the next decade.

[1]  A. So,et al.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. , 2010, Arthritis and rheumatism.

[2]  J. Schold,et al.  Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response , 2010, International Journal of Obesity.

[3]  J. Tschopp,et al.  Thioredoxin-interacting protein links oxidative stress to inflammasome activation , 2010, Nature Immunology.

[4]  M. Caulfield,et al.  Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. , 2010, Human molecular genetics.

[5]  P. Hawkins,et al.  Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.

[6]  J. Erdmann,et al.  Common Polymorphisms Influencing Serum Uric Acid Levels Contribute to Susceptibility to Gout, but Not to Coronary Artery Disease , 2009, PloS one.

[7]  J. Singh,et al.  Progress in Measurement Instruments for Acute and Chronic Gout Studies , 2009, The Journal of Rheumatology.

[8]  R. Terkeltaub,et al.  The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study , 2009, Annals of the rheumatic diseases.

[9]  Christian Gieger,et al.  Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations , 2009, PLoS genetics.

[10]  F. Martinon,et al.  The inflammasomes: guardians of the body. , 2009, Annual review of immunology.

[11]  Hyon K. Choi,et al.  Vitamin C intake and the risk of gout in men: a prospective study. , 2009, Archives of internal medicine.

[12]  A. Hofman,et al.  Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study , 2008, The Lancet.

[13]  H. Schumacher,et al.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.

[14]  T. Merriman,et al.  Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout. , 2008, Rheumatology.

[15]  P. Elliott,et al.  SLC2A9 Is a High-Capacity Urate Transporter in Humans , 2008, PLoS medicine.

[16]  L. Moreland,et al.  Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. , 2008, Arthritis and rheumatism.

[17]  Richard J. Johnson,et al.  Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. , 2008, JAMA.

[18]  M. A. van de Laar,et al.  A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout , 2008, Annals of the rheumatic diseases.

[19]  A. Surprenant,et al.  P2X7 Receptor Differentially Couples to Distinct Release Pathways for IL-1β in Mouse Macrophage1 , 2008, The Journal of Immunology.

[20]  L. Kuller,et al.  Long-term cardiovascular mortality among middle-aged men with gout. , 2008, Archives of internal medicine.

[21]  S. Wiedmann,et al.  Association of Common Polymorphisms in GLUT9 Gene with Gout but Not with Coronary Artery Disease in a Large Case-Control Study , 2008, PloS one.

[22]  Hyon K. Choi,et al.  Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study , 2008, BMJ : British Medical Journal.

[23]  S. Bandinelli,et al.  The GLUT9 Gene Is Associated with Serum Uric Acid Levels in Sardinia and Chianti Cohorts , 2007, PLoS genetics.

[24]  F. Martinon,et al.  Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration , 2007, Cell Death and Differentiation.

[25]  Hyon K. Choi,et al.  Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease , 2007, Circulation.

[26]  W. Willett,et al.  Coffee consumption and risk of incident gout in men: a prospective study. , 2007, Arthritis and rheumatism.

[27]  J. Tschopp,et al.  A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.

[28]  W. Grassi,et al.  High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study , 2006, Annals of the rheumatic diseases.

[29]  S. Holland,et al.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.

[30]  N. Dalbeth,et al.  Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. , 2006, The Journal of rheumatology.

[31]  D. Furst,et al.  Gout and the risk of acute myocardial infarction. , 2006, Arthritis and rheumatism.

[32]  S. Akira,et al.  MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. , 2006, The Journal of clinical investigation.

[33]  P Netter,et al.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[34]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[35]  H. Schumacher,et al.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.

[36]  H. Schumacher,et al.  Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? , 2005, The American journal of medicine.

[37]  Hyon K. Choi,et al.  Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. , 2005, Archives of internal medicine.

[38]  A. Tausche,et al.  Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor α as a new therapeutic option , 2004, Annals of the rheumatic diseases.

[39]  O. Florey,et al.  Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. , 2004, Arthritis and rheumatism.

[40]  W. Willett,et al.  Alcohol intake and risk of incident gout in men: a prospective study , 2004, The Lancet.

[41]  J. Moley,et al.  Identification and Characterization of Human Glucose Transporter-like Protein-9 (GLUT9) , 2004, Journal of Biological Chemistry.

[42]  Elizabeth W Karlson,et al.  Purine-rich foods, dairy and protein intake, and the risk of gout in men. , 2004, The New England journal of medicine.

[43]  F. Martinon,et al.  NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. , 2004, Immunity.

[44]  L. Truong,et al.  A role for uric acid in the progression of renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[45]  J. Callebert,et al.  Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. , 2002, Arthritis and rheumatism.

[46]  S. McColl,et al.  Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis , 1995, The Journal of experimental medicine.

[47]  W. Martin,et al.  Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. , 2009, Arthritis and rheumatism.

[48]  William A. Richardson,et al.  SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout , 2008, Nature Genetics.

[49]  C. Gieger,et al.  SLC2A9 influences uric acid concentrations with pronounced sex-specific effects , 2008, Nature Genetics.